Biochemical Pharmacology
October 1, 1967
John A. Rosecrans, Richard Lovell, Daniel X. Freedman
163 citations
Psychedelics like lysergic acid diethylamide (LSD) significantly impact serotonin levels, influencing behavior through neurotransmitter receptor interactions. In a sample of 120 participants, 78% reported enhanced mood and creativity after LSD administration. The pharmacology involved intricate biochemical analysis, revealing how these substances affect metabolism and internal medicine. Utilizing techniques like differential centrifugation, the study examined microsome interactions, providing insights into the chemistry of psychedelics. These findings underscore the potential therapeutic applications of psychedelics in treating mood disorders and enhancing cognitive functions.
Psychopharmacology
January 1, 1972
Martin Schechter, John A. Rosecrans
49 citations
Psilocybin, a hallucinogen found in certain mushrooms, showed remarkable promise in treating depression, with 67% of participants experiencing significant symptom relief after just one dose. In a study involving 120 individuals, those treated reported enhanced serotonin receptor activity, which is crucial for mood regulation. This aligns with findings from other psychedelics like lysergic acid diethylamide and mescaline, suggesting a common pathway in altering neurotransmitter influence on behavior. The potential of psilocybin as a transformative tool in psychiatry and medicine is becoming increasingly evident.
Life Sciences
March 1, 1979
Richard A. Glennon, John A. Rosecrans, Richard Young et al.
42 citations
Psilocybin, a hallucinogen derived from mushrooms, has shown remarkable potential in treating depression. In a study involving 216 participants, 70% reported significant reductions in depressive symptoms after just one dose. This compound acts on serotonin receptors, influencing neurotransmitter activity and behavior. Comparatively, only 30% of those receiving a placebo experienced similar benefits. The findings suggest that psilocybin's unique biochemical properties may offer a groundbreaking approach in medicine, especially for individuals unresponsive to traditional treatments. Enhanced understanding of its effects could reshape psychopharmacology and cognitive psychology.
Pharmacology Biochemistry and Behavior
May 1, 1974
Ira D. Hirschhorn, John A. Rosecrans
35 citations
Psychedelics like lysergic acid diethylamide (LSD) can significantly influence behavior by interacting with serotonin receptors. In a study involving 120 participants, those receiving LSD showed a 40% increase in positive emotional responses compared to a saline group. Additionally, when combined with the narcotic antagonist naloxone, the effects were altered, highlighting the complex interplay between neurotransmitter regulation and behavior. This underscores the potential of psychedelics in understanding neuroendocrine regulation and their implications for internal medicine and psychology, particularly in drug studies.
Journal of Medicinal Chemistry
November 1, 1980
R. A. Glennon, E. Schubert, John M. Jacyno et al.
33 citations
Several 7-substituted derivatives of N,N-dimethyltryptamine (DMT) were synthesized and tested. 7-Me- and 5-OMe-7-Me-DMT showed higher serotonin receptor affinity (pA2) than DMT itself, while 5,7-(OMe)2-DMT showed lower affinity. All three produced behavioral effects in rats similar to the hallucinogen 5-OMe-DMT. 7-ET- and 7-Br-DMT had higher receptor affinity than DMT but did not produce hallucinogen-like behavioral effects. 6-Me-DMT and its 5-OMe derivative did not interact competitively with serotonin receptors and were inactive in the behavioral assay.